* Ikena Oncology Inc is expected to show a fall in quarterly revenue when it reports results on November 7 (estimated) for the period ending September 30 2024
*
* LSEG's mean analyst estimate for Ikena Oncology Inc is for a loss of 27 cents per share.
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Ikena Oncology Inc is $4.00, above its last closing price of $1.69.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Jun. 30 2024 -0.33 -0.35 -0.28 Beat 19.4
Mar. 31 2024 -0.41 -0.41 -0.33 Beat 20
Dec. 31 2023 -0.43 -0.47 Missed -9.8
Sep. 30 2023 -0.42 -0.43 -0.40 Beat 7
Jun. -0.46 -0.47 -0.44 Beat 7.3
30 2023
Mar. 31 2023 -0.47 -0.47 -0.39 Beat 16.6
Dec. 31 2022 -0.53 -0.48 -0.40 Beat 16.1
Sep. 30 2022 -0.48 -0.50 -0.48 Beat 3.1
This summary was machine generated November 6 at 14:15 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。